Nomad Power Solutions, Inc. (NMAD) stock
Close on Nov 18, 2026Market cap $45.89MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $45.89M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.92
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$6.08M
- EPS, diluted
- -$1.00
- Book value per share
- $1.77
- Diluted shares
- 13M
Trading
- Previous close
- $3.00
- Open
- $2.96
- Day's range
- $2.54 – $2.99
- Volume
- 347,117
- Average volume (20 days)
- 269,395
- 52-week range
- $2.15 – $8.38
- RSI (14 days)
- 38.8
- Volatility (1 year)
- 104.2%
- Relative volume
- 1.31×
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | NMAD | S&P 500 | Difference | NMAD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.5% | -4.3% | −22.2 pts | ||
| 3 months | -32.5% | -4.6% | −27.8 pts | ||
| Year to date | -27.5% | +7.9% | −35.4 pts | ||
| 1 year | -34.3% | +11.8% | −46.1 pts | ||
| 3 years | -5.0% | +68.0% | −73.0 pts | -1.7% | +18.9% |
| 5 years | -83.4% | +66.2% | −149.6 pts | -30.2% | +10.7% |
| 10 years | -76.2% | +291.3% | −367.6 pts | -13.4% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Nomad Power Solutions filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Nomad Power Solutions
Pharmaceutical Preparations
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton therapy enterprise focused on discovering, developing, and commercializing cancer therapies. The organization centers its primary pharmaceutical pipeline on inhibitors of protein phosphatase 2A, targeting their capability to augment the effectiveness of chemotherapy, radiation, and immunotherapy treatments. Its principal investigational asset, designated as LB-100, is undergoing evaluation across several clinical trials, including investigations for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. In parallel, through its majority ownership in Liora Technologies Europe Ltd., the company develops electronically controlled proton therapy equipment using proprietary linear accelerator systems for tumor radiation.
Company profile, executives and historyNomad Power Solutions stock: common questions
What is Nomad Power Solutions's stock price?
NMAD closed at $2.85 on Nov 18, 2026, down 5.00% on the day. Over the past 52 weeks it traded between $2.15 and $8.38.
What is Nomad Power Solutions's market cap?
Nomad Power Solutions was worth $45.89M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is NMAD's P/E ratio?
Nomad Power Solutions lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.00), so it has no meaningful P/E ratio.
Does Nomad Power Solutions pay a dividend?
No. Nomad Power Solutions has not paid a cash dividend over the last twelve months.
How has NMAD stock performed over the past year?
Including dividends, NMAD returned -34.3% over the past year, against +11.8% for the S&P 500.
How many NMAD shares are sold short?
1M shares were sold short at the latest FINRA report, 6.14% of the float, or 4.2 days of average trading volume.
Who are Nomad Power Solutions's competitors?
Companies most similar to Nomad Power Solutions by business, industry and size include SLS, LSTA, KZIA, NBP, APLM.
See a number that looks wrong?